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SUPPLEMENTARY METHODS, FIGURES AND TABLES 
 
METHODS 
Histology. In GVHD experiments, histological damage was evaluated in the skin, liver, lung and 
kidney according to a semiquantitative scoring system based on histopathological analysis of 
routinely-stained haematoxylin and eosin 4-micra-thick tissue sections. In detail, epidermal 
necrosis, epidermal inflammatory infiltration, and dermal inflammatory infiltration were analysed 
in the skin; parenchymal inflammatory infiltration, peri-portal necrosis, and centro-lobular necrosis 
were assessed in the liver; interstitial inflammatory infiltration, epithelial proliferation, and stromal 
proliferation were scored in the lung parenchyma; glomerular rarefaction, glomerular necrosis, 
glomerular inflammatory infiltration, and interstitial inflammatory infiltration were evaluated in the 
kidney. Each variable was scored according to a four-grade semiquantitative score: 0 (absent), 1 
(focal/mild), 2 (multifocal/moderate), 3 (diffuse/intense). The final damage score was calculated for 
each experimental condition by averaging the scores relative to the same tissues.  
Lentiviral vector construction, virus production and MSC infection. To construct CXCR4-
expressing lentivector, we modified the self-inactivating lentiviral vector pRRLCMVGFPsin-18  
(kind gift of Dr. G. Ferrari) by replacing the GFP sequence with mouse CXCR4 cDNA (Genescript). 
A third-generation packaging system (pMDLg/pRRE and pRSV-REV and pMD2-VSV-G and 
transfer vectors) was used to produce viral particles. Lentiviral stocks were produced in 293T cells 
by Ca3PO4 co-trasfection of the four plasmids. Twenty-four hours after transfection, the virus 
containing supernatant was harvested, filtered and purified by ultracentrifugation. The viral titer 
was calculated by analysis of the expression of CXCR4 by flow cytometry in 293T cells infected 
with different dilution of virus. A MOI 50 was used to infect MSC. 
Real Time PCR. Total RNA was extracted by using the Quick RNA micro prep kit (Zymo 
Research) and subsequently quantified with NanoDrop 2000c Spectrophotometer (Thermo 
Scientific). MultiScribe-Reverse Transcriptase kit (Applied Biosystems) was used for the reverse 
transcription assay and the Real-Time PCR was performed using the Taqman Universal PCR 
Master Mix (Applied Biosystems) according to the manufacturer instructions. Briefly, the master 
mix, 20 ng of cDNA and the probes of interest were diluted in a total volume of 20 μL and the 
Real-Time PCR was performed on 7900HT Fast Real-Time PCR System (Applied Biosystems).  
Taqman Probes: Cd40 (Mm00441891_m1), Tnfsf4 (ox40l - Mm00437214_m1), Bglap 
(Mm03413826_mH), sp7 (osterix - Mm00504574_m1), pparg (Mm00440940_m1), runx2 
(Mm00501584_m1), sparc (Mm00486332_m1), spp1 (Mm00436767_m1). 
IHC and immunofluorescence analyses. For IHC, Human and Murine BM  samples were fixed in 
10% buffered formalin, decalcified using an EDTA-based buffer, and paraffin-embedded. Tissue 
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sections (4 µm) were deparaffinized and rehydrated. An antigen unmasking technique was 
performed using Novocastra Epitope Retrieval Solution (pH 9) in a PT Link Dako pre-treatment 
module at 98°C for 30 min. Subsequently, the sections were brought to room temperature and 
washed in PBS. After neutralization of the endogenous peroxidases with 3% H2O2 and Fc-blocking 
by a specific protein block (Novocastra, UK), the samples were incubated overnight at 4°C with 
primary antibodies listed in Supplementary Table 2.  The immunostaining was revealed by either a 
polymer detection method (Novolink  Polymer Detection Systems Novocastra Leica Biosystems 
Newcastle Ltd  Product No: RE7280-K), and following specific secondary antibodies: horseradish 
peroxidase (HRP)-conjugated donkey anti-rabbit IgG (H+L)(A16035, Invitrogen) or HRP-
conjugated goat anti-rat IgG (H+L) (Vector Lab) secondary antibody and either 3-amino-9-
ethylcarbazole (AEC) or 3,3’-diaminobenzidine (DAB) substrate-chromogens.  
For co-immunofluorescence, BM and spleen sections were pretreated as detailed above for 
IHC. The primary antibodies used for this analysis are detailed in Supplementary Table 2. Primary 
antibody binding was amplified and visualized using Alexa Fluor 568-conjugated goat anti-rabbit 
IgG (H+L) (A11011, Invitrogen), Alexa Fluor 488-conjugated goat anti-rat IgG (H+L) (A11006, 
Invitrogen), Alexa Fluor 488-conjugated goat-anti-mouse IgG (H+L) (A11001, Invitrogen), or 
Alexa Fluor 633-conjugated goat anti- rat IgG (H+L) (A21094, Invitrogen). The slides were 
counterstained with DAPI Nucleic Acid Stain (Invitrogen Molecular Probes). The samples were 
then analyzed under an Axioscope A1 optical microscope (Zeiss) and microphotographs were 
collected using an Axiocam 503 color digital camera (Zeiss). Images were analyzed using Zen2 
imaging software. 
The quantitative analysis of CD40 and PAX5 in BM biopsies from human samples by 
immunohistochemistry was performed on whole sections scans using a Leica Aperio CS2 slide 
scanner and by quantifying the staining by two different software tools. The Nulcear Hub tool 
(Nuclear v9) of the Image Scope software was used to determine the percentage of PAX5-
expressing nuclei over the total cellularity, while the Positive Pixel Count v9 tool was adopted to 









Gating strategy utilized to characterize B-cell development in mouse BM chimeras.  
a. Representative gating strategy for PB FACS analysis showing the frequencies of B220+, CD3 
and CD11b+ cells in the PB of WT>Cd40-KO BM chimeras compared to WT>WT BM chimeras. 
b.  Representative dot plots showing the gating strategy used to characterize BM B-cell 
development in chimeric mice. CD43+ B-cell precursors are identified within the B220+ gate. 
CD43+ cells are further characterized according to the expression of BP-1 and CD24 that allows to 
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distinguish among the different pre-pro and pro-B fractions (A, B, C and C’). Within the CD43- 
population the expression of IgM and B220 identified the fraction D, E and F c representative dot 
plots showing the different B-cell populations maturating in the spleens of WT>WT and WT> 
Cd40-KO BM chimeras. Splenic immature B220+CD93+ B-cell were divided into transitional T1, 
T2, and T3 cells based on their expression of CD23 and IgM (T1 = IgM + CD23-, T2 = IgM + 








Detection of B220+CD40+ B-cells in Cd40-KO recipient mice. a. Representative IF 
microphotographs of spleen sections from different chimeric mice showing the presence of 
B220+(green signal) CD40+(red signal) cells in the spleen of WT>WT and WT>Cd40-KO chimeras. 
In Cd40-KO>WT chimeras CD40 expression is confined to scattered CD45RB B220-negative 
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stromal elements while Cd40-KO>Cd40-KO controls have no detectable CD40 expression 
(Original magnification x400). b. Frequency of B220+CD43+ and B220+CD43- cells within the 






















































BM-MSC purification and phenotypic characterization. Phenotypic characterization of purified 
mesenchymal stem cells – Following the enzymatic digestion with collagenase 0,2 mg/mL, cell 
suspension is filtered by using 70  m cell strainers and incubated with the Lin antibody cocktail 
that includes CD45, CD11b, CD11c, CD3, GR-1, F4-80, B220, TER119 PE-conjugated. Then cells 
where labeled with Anti-PE MicroBeads (Miltenyi Biotech) and magnetically separated. 
Representative dot plots and the relative histograms of the samples pre- and post-purification are 
shown MSC phenotype was deeper investigated using CD34, CD31, CD29 and Sca-1 antibodies 















Expression of CD73 and CD40 on Sca-1+ and Sca-1neg BM-MSC MSCs. Representative gating 


































Treg	 behavior	 in	wt	 and	 cd40-KO	mice.	 a. Frequency	 of	 Teff	 and	 Treg	 within	 the	 spleen	 of	
irradiated	WT	and	Cd40-KO	mice.	 b.	Schematic representation of BMT experiments in which Lin- 
cell were co-injected with Treg cells into lethally irradiated WT and Cd40-KO mice. The use of 
CxB6 F1 mice (either WT or Cd40-KO) as recipients allowed discriminating donor and host Treg, 







































































Histological features of aGVHD mouse models. a. Schematic representation of the BMT 
experiment performed to obtain MHC-mismatched (modeling aGVHD) or non-MHC-mismatched 
BM chimeras. b Weight loss in aGVHD at day 21 after BMT in the specified allogeneic-
transplanted and control animals (n= 12 per group). **p < 0.005, compared using Student’s t test. c. 
Histological score for lung, liver, kidney and skin damage in aGVHD mice (TD-BM+Teff B6>B/c) 
and control groups.  d. Representative microphotographs detailing the different extent of immune 
infiltration and associated histological damage in the lung, kidney and liver parenchyma of mice 
belonging to the four groups. No significant immune cell infiltration is detected in the tissues of 
TD-BM B/c>B/c mice; slight inflammatory infiltration mainly confined to peri-vascular areas and 
without signs of parenchymal damage characterizes TD-BM B/c+Teff>B/c mice; Focally severe 
inflammatory infiltration associated with evidence of parenchymal damage is detected in TD-BM 
B6c>B/c mice samples; Multifocal or diffuse immune infiltration determines overt disarrangement 
of the histological architecture in the three organs of TD-BM B6+Teff>B/c mice.    
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MHC-I expression on Sca+ and Sca- BM-MSCs (CD29+CD44+) upon lethal irradiation. 
a. B-cells and b. Tregs at days 7, 14, and 21 post-allogeneic BMT compared to controls (n = 5 per 
group). ***p < 0.001, compared by Student’s t test. c. Representative gating strategy showing 
MHChighCD40+, MHChighCD40- and of MHCnegCD40+ BM-MSCs in the Sca-1+ gate and Sca-1neg 
gate of Lin-CD44+CD29+ BM-MSCs in aGVHD vs controls mice. The analysis was performed at 
14 days post-transplantation. d. Cumulative data displaying the increase MFI of MHC-I in 









































































































































****p < 0.0001, compared by Student’s t test. e. representative gating strategy of the cytotoxicity 











Supplementary Table 1. Patients characteristics.  
Patient 







ex ATG immunosuppression aGVHD cGVHD IHC Pax5 IHC CD40 
#1 d28 AML 59/m x Cyclosporine, Cellcept Grade III    <1% 1 (myelo) 
#2 d26 AML 45/m   Cyclosporine, MTX Grade III    <1% 0 
#3 d25 AML 57/f x Cyclosporine, Cellcept     6% 1 (myelo) 
#4 d21-28 T-NHL+tAML 71/f x Cyclosporine, Cellcept     21% 2 (myelo + stroma) 
#5 d21 AML 72/m x Cyclosporine, Cellcept   Grad III  <1% 0 
#6 d24 Ph+ ALL 58/f   Cyclosporine, MTX  Grade I    5% 2 (myelo) 
#7 d28 AML 43/f   Cyclosporine, MTX Grade II    3% 1 (myelo) 
#8 d28 AML 62/f x Cyclosporine, Cellcept     15% 2 (myelo + stroma) 
#9 d28 AML 57/m x Cyclosporine, Cellcept Grade II   8% 1 (myelo + stroma) 
#10 d22 AML 58/f x Cyclosporine, Cellcept     12% 1 (myelo + stroma) 
#11 d28 ALL 23/m   Cyclosporine, MTX Grade II   <1% 1 (myelo) 




Supplementary Table 2. List of antibodies. 
Fluorescence Antigen Clone Manufacturer 
BM ANALYSIS 
APC-eFluor 780 B220 RA3-6B2 eBioscience 
APC CD43 S7 BD 
PECy7 IgM R6-60.2 BD 
PE CD24 30-F1 BD 
PE B220 RA3-6B2 BD 
FITC BPI F6354 eBioscience 
SPLENIC B-CELL COMPOSITION 
FITC CD43 eBioR2/60 eBioscience 
APC-Cy7 B220 RA3-6B2 Biolegend 
APC CD93 AA4.1 eBioscience 
PE CD23 B3B4 eBioscience 
FITC IgD 11-26c eBioscience 
PerCP CD21/35 7E9 Biolegend 
APC CD3 145-2C11 BD 
PE CD11c N418 Tonbo Biosciences 
Pe-Cy7 CD11b M1/70 Tonbo Biosciences 




FITC CD25 eBio7D4 eBioscience 
FITC TNFα MP6-XT22 BD 
PE OX40 OX86 Biolegend 
PerCPCy5.5 Foxp3 FJK-16S eBioscience 
PE-Cy7 CD4 RM4-5 Tonbo Biosciences 
APC IFNγ XMG1.2 eBioscience 
APC-eFluor780 CD45.2 L104 Biolegend 
APC-eFluor780 CD45.1 A20 eBioscience 
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Fluorescence Antigen Clone Manufacturer 
BM-MSC ANALYSIS 
FITC CD45 30-F11 Tonbo Biosciences 
FITC CD31 390 eBioscience 
FITC TER119 Ter119 Invitrogen 
FITC CD34 RAM34 BD 
FITC cKIT 2B8 eBioscience 
APC SCA-1 D7 BD 
APC-Cy7 CD44 IM7 BD 
BV421 MHC-I AF6-88.5 BD 
BV605 CD73 TY/11.8 Biolegend 
BV711 MHC-II M5/114.15.2 BD 
PE CD40  3/23 BD 
BV421 CD40 3/23 BD 












CD40 (ab13545) polyclonal anti-
human and mouse 
1:100 Abcam 
iNOS (ab15323) polyclonal anti-
mouse 
1:100 Abcam 
PD-L1 (D5V3B) monoclonal anti-
mouse 






























polyclonal 1:100 Invitrogen 
 
 
 
